References
- Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14:135-46. doi:10.1038/nrc3670. PMID:24457417
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348:69-74. doi:10.1126/science.aaa4971. PMID:25838375
- Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Ph D, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90. doi:10.1056/NEJMoa051113. PMID:15858187
- Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369:2379-90. doi:10.1056/NEJMoa1311347. PMID:24325356
- Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369:2391-405. doi:10.1056/NEJMoa1312542. PMID:24325359
- Holmstrom MO, Hjortso MD, Ahmad SM, Met O, Martinenaite E, Riley C, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH. The JAK2V617F mutation is a target for specific T-cells in the JAK2V617F positive myeloproliferative neoplasms. Leukemia. 2017; 31:495-8. doi:10.1038/leu.2016.290. PMID:27761006
- Holmstrom MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia. 2016; 30:2413-6. doi:10.1038/leu.2016.233. PMID:27560107
- Holmstrom MO, Martinenaite E, Ahmad SM, Met O, Friese C, Kjaer L, Riley CH, thor Straten P, Svane IM, Hasselbalch HC et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 2017; doi:10.1038/leu.2017.214
- Andersen MH. Anti-regulatory T cells. Semin Immunopathol. 2017; 39:317-26. doi:10.1007/s00281-016-0593-x. PMID:27677755
- Kiladjian J-J, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone. Leukemia 2015; 30:1-6. doi:10.1038/leu.2015.326. PMID:26108693